Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Latest News
We've been hit by cyberattack, texts MSD Aust
Cyberattack: Phones and computers were out of action at MSD's offices in Aust, the US, Ireland and other countries today after the US pharma giant was hit by the latest act of cyber terrorism, named Petya.
Stada bid fails but game not over
Takeovers: An attempt by Bain Capital and Cinven to acquire massive German generics company Stada has failed but the business appears to still be in play.
Pfizer begins hunt for new HQ
Workplace: Pfizer has started searching for a new Australian head office as it continues to wrap up West Ryde manufacturing operations, with production set to cease by year's end.
Time to review NIP says CMO
Reimbursement: Meningococcal outbreaks have forced some states to fund their own immunisations, prompting the Chief Medical Officer to call for a review of how long it takes to reimburse vaccines.
Seqirus scores vax breakthrough
Innovation: CSL's vaccine arm Seqirus has notched up an industry first that will change the way flu vaxes are made.
Orphans driving pharma growth
Orphan drugs: With changes to the TGA's orphan drugs program set to take effect next week, a new report has predicted orphans will contribute a third of pharma's growth in the next five years.
Most Popular
Sydney CBD's Pill House gets another tenant
Workplace: Barangaroo is fast becoming the pharma epicentre of the Sydney CBD with Ogilvy Health joining two major pharmaceutical companies in moving to the waterfront precinct - and all to the same building.
NZ-style tenders proposed for PBS
Retail: Options for reform put forward by the King review in its interim report to government include that the PBS adopt tendering for generic medicine listings plus other changes likely to cause upheaval for pharmacos.
MSLs climbing the corporate ladder
Employment: The first comprehensive survey of medical affairs staff in Aussie pharma highlights that MSLs are moving into broader and more strategic roles.
New patent cliff looms over revenue
Revenue: An emerging patent cliff for biologics, totalling almost US$200 billion, has forced a key drug sales forecast to fall for the first time in a decade.
Are Aussie pharma sales reps underpaid?
Employment: Pharmaceutical sales reps in the US earn fifty per cent more than Australian sales reps but that may be about to change.
Industry unites against King review
PBS reform: Pharma's united voice, the Medicines Partnership of Australia, has added its own warning on the dangers of the King review's proposed reforms to those of individual peak bodies.
Is Gilead shopping to bolster pipeline?
Companies: An uptick in Gilead's share price last week is feeding speculation the company may be reaching into its multi-billion war chest.
Turnbull pressured on meningo vax
Vaccination: Labor is aiming its attack on the government's failure to place meningococcal W vax on the NIP directly at PM Malcolm Turnbull.
Osteoporosis treatment gap widening
Treatment Trends: A new report showing the cost of osteoporosis could be $3bn this year alone has led to 30 health and consumer groups forming an alliance to fight it.
PBS shrinking once you take out aberrations
Reimbursement: There's good reason why we hear little from government these days about an 'out of control' PBS. It's because the scheme's cost - once the hep C aberration is removed - is shrinking.
What's the King review think it's doing?
Is the King review sending industry a message that disruptive reform of the PBS is anything but over despite MA's agreement with government?
Approvals Action
First threat to $63m pain drug
Sandoz's new generic competitor could make a serious hole in the drug that represents close to 40 per cent of Mundipharma's total PBS earnings.
Pipeline Monitor
FDA issues flood of approvals
The US regulatory body issued a number of approvals this week including a new combination use for Janssen's oncology med Darzalex and two ADHD meds.
FREE Content
Events & Conferences
Pharma in Focus Jobs